We have developed several novel approaches for analysis of massively parallel gene expression datasets. First, StepMiner, a tool that identi?es step-wise transitions in the time course microarray datasets. Second, BooleanNet, a method of discovering Boolean implications between genes using these large numbers of gene expression datasets. Recently, we published a new method called MiDReG (Mining Developmentally Regulated Genes) that uses Boolean implications to successfully predict genes in developmental pathways. By initially applying this approach to lymphocyte differentitaion, we discovered previously unrecognized markers for B cell differentiation, as well as a novel branchpoint of B cell and T cell development. The proposed project will build on our successful prediction of human B cell developmental genes using MiDReG to develop a general method for discovering cancer stem and progenitor cells. I am planning to validate this approach in human bladder cancer (Transitional Cell Carcinoma), ?rst, because it is a simple model cancer to test, and, second, because our laboratory has the expertise to isolate and test cell populations for tumor-initiating potential. This method will be optimized for the discovery of stem and progenitor cells in bladder cancer and hopefully it will serve as a starting point for similar studies in other types of cancers. More than 90% of human bladder cancers arise from a simple epithelial tissue called urothelium, and are commonly called transitional cell carcinomas (TCC). Furthermore, human bladder cancer is ?fth most common cancer in the United States. Our laboratory has established a working model for the xenotransplantation of human bladder cancer in mice and has recently discovered a tumor-initiating population in bladder cancer. Recent studies show that cancer is heterogeneous and forms a hierarchy of original tumor cell populations. However, a detailed bladder cancer developmental hierarchy remains unknown. My primary near-term goal in this proposal is to understand this hierarchy of bladder cancer cells using a systems biology approach to predict (diagnostic/prognostic) genes that mark speci?c populations. I will validate this approach using human cancer tissue microarrays in collaboration with Dr. Matt van de Rijn ,and using xenotransplantation in collaboration with Drs. Robert Chin and Jens-Peter Volkmer. In the longer term, I will extend the method to identify stem and progenitor cells in other types of cancers during my independent investigator phase.

Public Health Relevance

Identi?cation of cancer stem and progenitor cells contributes strongly to the understanding of development and differentiation of cancer. Cancer stem cells may be at the core of the resistance of cancers to conventional therapies, and are thus likely the target of future cancer treatments. Also, identi?cation of cancer stem cells may aid in understanding the normal developmental process. Tissue stem cells have long term regenerative potential that may be used to regenerate injured or diseased organs. The identi?cation of hematopoietic stem cells, for example, has substantially changed both how we understand the normal developmental process and how we approach treatment of hematological disease. Knowledge about these cells will play a pivotal role in developing better ways to combat human diseases. Our ?ndings will be relevant to the mission of the NIH because it has a direct impact on human health.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Transition Award (R00)
Project #
5R00CA151673-05
Application #
9124717
Study Section
Special Emphasis Panel (NSS)
Program Officer
Li, Jerry
Project Start
2014-07-01
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dalerba, Piero; Sahoo, Debashis; Clarke, Michael F (2016) CDX2 as a Prognostic Biomarker in Colon Cancer. N Engl J Med 374:2184
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Skelton, Rhys J P; Brady, Bevin; Khoja, Suhail et al. (2016) CD13 and ROR2 Permit Isolation of Highly Enriched Cardiac Mesoderm from Differentiating Human Embryonic Stem Cells. Stem Cell Reports 6:95-108
Krampitz, Geoffrey Wayne; George, Benson M; Willingham, Stephen B et al. (2016) Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 113:4464-9
Chen, James Y; Miyanishi, Masanori; Wang, Sean K et al. (2016) Hoxb5 marks long-term haematopoietic stem cells and reveals a homogenous perivascular niche. Nature 530:223-7
Cheah, Ming T; Chen, James Y; Sahoo, Debashis et al. (2015) CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A 112:4725-30
Chan, Charles K F; Seo, Eun Young; Chen, James Y et al. (2015) Identification and specification of the mouse skeletal stem cell. Cell 160:285-98
Shin, Kunyoo; Lim, Agnes; Zhao, Chen et al. (2014) Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26:521-33
Dimov, Ivan K; Lu, Rong; Lee, Eric P et al. (2014) Discriminating cellular heterogeneity using microwell-based RNA cytometry. Nat Commun 5:3451